全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

Consequences of Neglect: Analysis of the Sub-Saharan African Snake Antivenom Market and the Global Context

DOI: 10.1371/journal.pntd.0001670

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background The worldwide neglect of immunotherapeutic products for the treatment of snakebite has resulted in a critical paucity of effective, safe and affordable therapy in many Third World countries, particularly in Africa. Snakebite ranks high among the most neglected global health problems, with thousands of untreated victims dying or becoming permanently maimed in developing countries each year because of a lack of antivenom—a treatment that is widely available in most developed countries. This paper analyses the current status of antivenom production for sub-Saharan African countries and provides a snapshot of the global situation. Methods A global survey of snake antivenom products was undertaken in 2007, involving 46 current and former antivenom manufacturers. Companies producing antivenom for use in sub-Saharan Africa were re-surveyed in 2010 and 2011. Results The amount of antivenom manufactured for sub-Saharan Africa increased between 2007 and 2010/11, however output and procurement remained far below that required to treat the estimated 300,000–500,000 snakebite victims each year. Variable potency and inappropriate marketing of some antivenoms mean that the number of effective treatments available may be as low as 2.5% of projected needs. Five companies currently market antivenom for sale in Africa; three others have products in the final stages of development; and since 2007 one has ceased production indefinitely. Most current antivenom producers possess a willingness and capacity to raise output. However inconsistent market demand, unpredictable financial investment and inadequate quality control discourage further production and threaten the viability of the antivenom industry. Conclusion Financial stimulus is urgently needed to identify and develop dependable sources of high-grade antivenoms, support current and emerging manufacturers, and capitalise on existing unutilised production capacity. Investing to ensure a consistent and sustainable marketplace for efficacious antivenom products will drive improvements in quality, output and availability, and save thousands of lives each year.

 References

[1]  Winkel K, Mirtschin P, Pearn J (2006) Twentieth century toxinology and antivenom development in Australia. Toxicon 48: 738–754. doi: 10.1016/j.toxicon.2006.08.001
[2]  Abubakar IS, Abubakar SB, Habib AG, Nasidi A, Durfa N, et al. (2008) Randomised Controlled Double-Blind Non-Inferiority Trial of Two Antivenoms for Saw-Scaled or Carpet Viper (Echis ocellatus) Envenoming in Nigeria. PLoS Negl Trop Dis 4: e767. doi:10.1371/journal.pntd.0000767.
[3]  Gold SG, Dart RC, Barish RA (2002) Bites of venomous snakes. N Engl J Med 347: 347–356. doi: 10.1056/NEJMra013477
[4]  Gutierrez JM (2007) Animal Antisera Production; Quality, safety and efficacy problems, Instituto Clodomiro Picado, Universidad de Costa Rica. Presentation to WHO. Available at: www.who.int/bloodproducts/animal/J.M.Gut？ierrezUniversidadCostaRica.pdf. Accessed Nov 11.
[5]  Harrison RA, Hargreaves A, Wagstaff SC (2009) Snake Envenoming: A disease of poverty. PLoS Negl Trop Dis 3: e569. doi: 10.1371/journal.pntd.0000569
[6]  Williams DJ, Gutierrez JM, Harrison R, et al. (2010) The Global Snakebite Initiative: An antidote for snake bite. Lancet 375: 89–91. doi: 10.1016/S0140-6736(09)61159-4
[7]  Theakston D, Warrell D (2000) Crisis in snake antivenom supply for Africa. The Lancet 356: 2104.
[8]  Williams D, Gutierrez JM, Calvette JJ, et al. (2011) Ending the Drought: New Strategies for Improving the flow of affordable, effective antivenoms in Asia and Africa. Journal of Proteomics 74: 1735–67. doi:10.1016/j.jprot.2011.05.027.
[9]  Chippaux JP (1998) The development and use of immunotherapy in Africa. Toxicon 36: 1503–1506. doi: 10.1016/S0041-0101(98)00140-8
[10]  Stock RP, Massougbodji A, Alagon A, Chippaux JP (2007) Bringing antivenoms to sub-Saharan Africa, Nature Biotechnology 25: 173–177. doi: 10.1038/nbt0207-173
[11]  WHO (2010) Snake Antivenoms. Fact Sheet no. 337 May 2010. Available at: http://www.who.int/mediacentre/factsheet？s/fs337/en/index.html.
[12]  Warrell DA (2008) Unscrupulous marketing of snakebite antivenoms in Africa: what's in a name? Trans R Soc Trop Med and Hygiene 102: 397–399. doi: 10.1038/nbt0207-173
[13]  Chippaux JP (2005) Evaluation de la situation épidemiologique et des capacités de prise en charge des envenimations ophidiennes en Afrique subsaharienne francophone, Bull Soc Path Exo 98: 264. doi: 10.1038/nbt0207-173
[14]  Chippaux JP (2002) Perspectives in Molecular Toxinology. Ménez A, editor. London: Wiley & Sons. pp. 457–472.
[15]  WHO (2007) Rabies and envenomings: a neglected public health issue. 14 p. Available at: http://www.who.int/bloodproducts/animal_？sera/Rabies.pdf. Accessed 2012, April 12.
[16]  Kasturiratne A, Wickremasinghe AR, de Silva N, et al. (2008) The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. PLoS Med 5: e218. doi: 10.1371/journal.pmed.0050218
[17]  Chippaux JP (1998) Snake-bites: appraisal of the global situation. Bull World Health Organ 75: 515–24.
[18]  Chippaux JP, Diof A, Stock RP, et al. (2011) Report of the 4th international conference on envenomations by snakebites and scorpion stings in Africa, Dakar. Toxicon 58: 426–9. doi: 10.1016/j.toxicon.2011.08.002
[19]  Swaroop S, Grabb B (1954) Snakebite mortality in the world. Bull World Health Organ 10: 35–76.
[20]  WHO (2008) WHO guidelines for the production, control and regulation of antivenom immunoglobulins. Released 2008. Available at: http://www.who.int/bloodproducts/snake_a？ntivenoms/snakeantivenomguide/en/ Accessed April 12.
[21]  Chippaux JP, Ramos-Cerrillo B, Stock RP (2007) Study of the efficacy of the black stone on envenomation by snake bite in the murine model. Toxicon 49: 717–720. doi: 10.1016/j.toxicon.2006.11.002
[22]  Chippaux JP (2011) Estimate of the burden of snakebite in sub-Saharan Africa: a meta-analytic approach. Toxicon 57: 586–599. doi: 10.1016/j.toxicon.2010.12.022
[23]  Snow RW, Bronzan R, Rogest T, Niamawi C, Murthy S, et al. (1994) The prevalence and morbidity of snake bite and treatment seeking behaviour among a rural Kenyan population. Ann Trop Med Parasitol 88: 668.
[24]  Chippaux JP (2002) Epidémiologie des morsures de serpent en République de C？te d'Ivoire, Bull Soc Path Exo 95: 167.
[25]  Chippaux JP, Rage-Andrieu V, Le Mener-Delore V, et al. (2002) Epidémiologie des envenimations ophidiennes dans le Nord du Cameroun. Bull Soc Path Exo 95: 185.
[26]  Warrell DA, Arnett C (1976) The importance of bites by the saw-scaled or carpet viper (Echis carinatus): epidemiological studies in Nigeria and a review of the world literature. Acta Trop 33: 307–41.
[27]  Chippaux JP (2007) Socioeconomic cost of envenomations in sub-Saharan Africa. Presentation to WHO consultative meeting Available at: ://www.who.int/bloodproducts/snake_antive？noms/rabies_envenomings/en/index.html. Accessed May 11.
[28]  McNamee D (2001) Tackling venomous snake bites worldwide. The Lancet 357: 1680.
[29]  Gutiérrez JM, Theakston RDG, Warrell DA (2006) Confronting the Neglected Problem of Snake Bite Envenoming: The Need for a Global Partnership. PLoS Med 3: e150. doi:10.1371/journal.pmed.0030150.
[30]  Nasidi A (2007) Snakebite as a serious public health problem for Nigeria and Africa. Available at: http://www.who.int/bloodproducts/snake_a？ntivenoms/rabies_envenomings/en/index.ht？ml. Accessed Jun 11.
[31]  Warrell DA (2007) Prequalification of therapeutic sera: a neglected public health need, Outcomes of a WHO Consultative Meeting, “Rabies and envenomings: a neglected public health issue”, 10 January 2007. Available at: http://www.who.int/bloodproducts/snake_a？ntivenoms/rabies_envenomings/en/index.ht？ml. Accessed May 11.
[32]  Padilla A (2007) Improving safety and availability of animal derived sera for therapeutic use. Presented at WHO Consultative meeting, January 2007. Available at: http://www.who.int/bloodproducts/snake_a？ntivenoms/rabies_envenomings/en/index.ht？ml. Accessed May 11).
[33]  Visser LE, Kyei-Faried S, Belcher DW, et al. (2008) Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. T Roy Soc Trop Med H 102: 445–450.
[34]  Simpson ID, Norris RL (2007) Snake Antivenom Product Guidelines in India: “The Devil is in the Details”. WEMJ 18: 163–168. doi: 10.1580/07-weme-ed-099r.1
[35]  Warrell DA, Williams DJ (2009) Response to comment on: Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance. T Roy Soc Trop Med H 103: 965–966. doi: 10.1580/07-weme-ed-099r.1
[36]  Sharma N, Chauhan S, Faruqi S, et al. (2005) Snake envenomation in a north Indian hospital. Emerg Med J 22: 118–120. doi:10.1136/emj.2003.008458.
[37]  Dart RC, Seifert SA, Boyer LV, et al. (2001) A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab (Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United States. Arch Intern Med 161: 2030–2036. doi: 10.1001/archinte.161.16.2030
[38]  Protherics PLCAnnual Report 2008. Available at: http://www.btgplc.com/investors/reports-？and-accounts/protherics-archive. Accessed February 12.
[39]  Brown N, Kevat D (2010) A legal antidote is needed to combat snake bite tragedy. New Scientist 207: 24–25. doi: 10.1016/s0262-4079(10)62138-0
[40]  Brown N, Landon J (2010) Antivenom: the most cost-effective treatment in the world? Toxicon 55: 1405–7. doi: 10.1016/j.toxicon.2010.02.012
[41]  Guidlolin RG, Marcelino RM, Gonda HH, et al. (2010) Polyvalent horse F(Ab′)2 snake antivenom: Development of process to produce polyvalent horse F(Ab′)2 antibodies anti-African snake venom. African Journal of Biotechnology 9: 2446–2455. doi: 10.1016/s0262-4079(10)62138-0
[42]  Ramos Cerrilo B, Adolfo R de R, Chippaux JP, et al. (2008) Characterization of a new polyvalent antivenom (Antivipmyn？ Africa) against African vipers and elapids. Toxicon 52: 881–888. doi: 10.1016/j.toxicon.2008.09.002
[43]  Calvete JJ, Cid P, Sanz L, et al. Antivenomic Assessment of the Immunological Reactivity of EchiTAb-Plus-ICP, an Antivenom for the Treatment of Snakebite Envenoming in Sub-Saharan Africa. Am J Trop Med Hyg 82: 1194–1201. doi: 10.4269/ajtmh.2010.09-0733
[44]  Chippaux JP, Massougbodji A, Stock RP, et al. (2007) Clinical Trial of an F(ab′)2 Polyvalent Equine Antivenom for African Snake Bites in Benin. Am J Trop Med Hyg 77: 538–546.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133